Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Jost

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignanciesR A Stahel, L M Jost, T Cerny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II studyM Jermann, L M Jost, Ch Taverna, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1989
Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumorsR A Stahel, J P Sculier, L M Jost, et al.
British Journal of Haematology|April 7, 1999
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remissionR A Stahel, L M Jost, T Kroner, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignanciesR A Stahel, L M Jost, T Cerny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II studyM Jermann, L M Jost, Ch Taverna, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1989
Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumorsR A Stahel, J P Sculier, L M Jost, et al.
British Journal of Haematology|April 7, 1999
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remissionR A Stahel, L M Jost, T Kroner, et al.
Pageof 4